In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...

Speaking to the Commons business and trade select committee on Tuesday, AstraZeneca’s chairman Shaun Grady confirmed that delays in securing a £90 million government contribution led to the collapse ...

Covington & Burling's London operation has advised pharmaceuticals giant AstraZeneca on its $1 billion acquisition of EsoBiotec, a Belgian biotechnology company specialising in vivo cell therapies.

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The company’s shares closed yesterday at p11,904.00.

AstraZeneca will leverage Alteogen’s platform technology to develop the therapies. Credit: © AstraZeneca 2025. AstraZeneca has entered an exclusive licence ...

Image credit: Kateryna Kon / Shutterstock. UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso ...

Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology. AstraZeneca capped off a hectic Monday with a ...

AstraZeneca is buying EsoBiotec for up to $1 billion for the company’s in vivo CAR-T cell drugs, or therapies that reprogram immune cells directly within patients' bodies. Analysts say the deal ...

AstraZeneca is set to acquire biotechnology firm EsoBiotec for up to $1 billion, including a $425 million upfront payment and up to $575 million contingent on milestones. EsoBiotec's ENaBL platform ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...